Shots: The FDA’s De novo clearance is based on five clinical studies in 600+ children diagnosed with ADHD, which demonstrated an improved measure of attention. After 4wks., one-third of children had no longer measurable attention deficit on at least one measure of objective attention Change in child’s day-to-day impairments following @1mos. treatment with EndeavorRx which […]Read More
